Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation
Biosimilar Hyrimoz® citrate-free high-concentration formulation is now approved in the EU for use in all indications of reference medicine Humira®*HCF formulation adalimumab offers patients... | April 3, 2023
Source: marketscreener.com